An update on therapies for the treatment of diabetes-induced osteoporosis

Sahar Mohsin, May M.Y.H. Baniyas, Reem S.M.H. AlDarmaki, Kornélia Tekes, Huba Kalász, Ernest A. Adeghate

Research output: Contribution to journalReview articlepeer-review

83 Citations (Scopus)


Introduction: Currently, 424 million people aged between 20 and 79 years worldwide are diabetic. More than 25% of adults aged over 65 years in North America have Type 2 diabetes mellitus (DM). Diabetes-induced osteoporosis (DM-OS) is caused by chronic hyperglycemia, advanced glycated end products and oxidative stress. The increase in the prevalence of DM-OS has prompted researchers to develop new biological therapies for the management of DM-OS. Areas covered: This review covered the current and novel biological agents used in the management of DM-OS. Data were retrieved from PubMed, Scopus, American Diabetes Association and International Osteoporosis Foundation websites, and The keywords for the search included: DM, osteoporosis, and management. Expert opinion: Several biological molecules have been examined in order to find efficient drugs for the treatment of DM-OS. These biological agents include anti-osteoporosis drugs: net anabolics (parathyroid hormone/analogs, androgens, calcilytics, anti-sclerostin antibody), net anti-resorptive osteoporosis drugs (calcitonin, estrogen, selective estrogen receptor modulators, bisphosphonates, RANKL antibody) and anti-diabetic drugs (alpha glucosidase inhibitors, sulfonylureas, biguanides, meglitinides, thiazolidinediones, GLP-1 receptor agonists, dipeptidylpeptidase-4 inhibitors, sodium glucose co-transporter-2 inhibitors, insulin). Biological medications that effectively decrease hyperglycemia and, at the same time, maintain bone health would be an ideal drug/drug combination for the treatment of DM-OS.

Original languageEnglish
Pages (from-to)937-948
Number of pages12
JournalExpert Opinion on Biological Therapy
Issue number9
Publication statusPublished - 2019


  • Diabetes-induced osteoporosis
  • anti-diabetic drugs
  • anti-osteoporosis drugs
  • bone
  • bone mineral density
  • hormones

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry


Dive into the research topics of 'An update on therapies for the treatment of diabetes-induced osteoporosis'. Together they form a unique fingerprint.

Cite this